Henlius’ Ophthalmic Bevacizumab Program Moves Ahead
IND Approval From US FDA Follows Nod From Australia’s TGA
Shanghai Henlius Biotech is planning to move forward with wet AMD trials for its bevacizumab biosimilar rival to Avastin following a nod from the US FDA.
You may also be interested in...
Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.
China’s Henlius has received international recognition of Phase I and III clinical trial results for its bevacizumab biosimilar, HLX04, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab.” The company has submitted its NDA for the product to the NMPA for various indications.
Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.